{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:22:21Z","timestamp":1778559741821,"version":"3.51.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,9]]},"DOI":"10.7759\/cureus.59978","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:55:28Z","timestamp":1715270128000},"source":"Crossref","is-referenced-by-count":3,"title":["FDA-Approved Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitors for Managing Rheumatoid Arthritis: A Narrative Review of the Literature"],"prefix":"10.7759","author":[{"given":"Tejaswini","family":"Potlabathini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounica  A","family":"Pothacamuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkata Varshitha","family":"Bandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnoor","family":"Anjum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parmendra","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilashis","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandr","family":"Adzhymuratov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midhun","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vatsalya","family":"Sadu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiza A","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harini","family":"Lingamgunta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Sahotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Muhammad Zain Jamil","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine Dawn M","family":"Daguipa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.7.1207","article-title":"A case of rheumatoid vasculitis involving hepatic artery in early rheumatoid arthritis","volume":"32","author":"Lee JE","year":"2017","unstructured":"Lee JE, Kim IJ, Cho MS, Lee J. A case of rheumatoid vasculitis involving hepatic artery in early rheumatoid arthritis. J Korean Med Sci. 2017, 32:1207-10. 10.3346\/jkms.2017.32.7.1207","journal-title":"J Korean Med Sci"},{"key":"ref2","article-title":"Physician Assistant Clinical Review Cards","author":"Fox CQ","year":"2002","unstructured":"Fox CQ. Physician Assistant Clinical Review Cards. F. A. Davis Company, Philadelphia (PA); 2002."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes IB","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011, 365:2205-19. 10.1056\/NEJMra1004965","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.21","article-title":"Rheumatoid arthritis: current and future trends","volume":"15","author":"Chaudhari K","year":"2016","unstructured":"Chaudhari K, Rizvi S, Syed BA. Rheumatoid arthritis: current and future trends. Nat Rev Drug Discov. 2016, 15:305-6. 10.1038\/nrd.2016.21","journal-title":"Nat Rev Drug Discov"},{"key":"ref5","article-title":"One year in review: the pathogenesis of rheumatoid arthritis","volume":"33","author":"Picerno V","year":"2015","unstructured":"Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A. One year in review: the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2015, 33:551-8.","journal-title":"Clin Exp Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.07.001","article-title":"Epidemiology of rheumatic musculoskeletal disorders in the developing world","volume":"22","author":"Chopra A","year":"2008","unstructured":"Chopra A, Abdel-Nasser A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Pract Res Clin Rheumatol. 2008, 22:583-604. 10.1016\/j.berh.2008.07.001","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2006.08.006","article-title":"Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review","volume":"36","author":"Alamanos Y","year":"2006","unstructured":"Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006, 36:182-8. 10.1016\/j.semarthrit.2006.08.006","journal-title":"Semin Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu328","article-title":"Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era","volume":"54","author":"McGonagle D","year":"2015","unstructured":"McGonagle D, Hermann KG, Tan AL. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford). 2015, 54:29-38. 10.1093\/rheumatology\/keu328","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","article-title":"Medicine Morning Report: Beyond the Pearls, 2nd Edition","author":"Piyarulli D","year":"2016","unstructured":"Piyarulli D, Koolaee R. Medicine Morning Report: Beyond the Pearls, 2nd Edition. Elsevier, 2016. 65-77."},{"key":"ref10","article-title":"Arthrogryposis: A Text Atlas","author":"Staheli L","year":"1998","unstructured":"Staheli L, Hall JA, Jaffe KM, Paholke DO. Arthrogryposis: A Text Atlas. Cambridge University Press, UK; 1998."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel L","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al.. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021, 73:1108-23. 10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020, 79:685-99. 10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012658","article-title":"Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: systematic review protocol","volume":"97","author":"Del Grossi Moura M","year":"2018","unstructured":"Del Grossi Moura M, Cruz Lopes L, Silva MT, Barberato-Filho S, Motta RH, Bergamaschi CC. Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: systematic review protocol. Medicine (Baltimore). 2018, 97:e12658. 10.1097\/MD.0000000000012658","journal-title":"Medicine (Baltimore)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes032","article-title":"Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative","volume":"51","author":"Whittle SL","year":"2012","unstructured":"Whittle SL, Colebatch AN, Buchbinder R, et al.. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford). 2012, 51:1416-25. 10.1093\/rheumatology\/kes032","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3528-y","article-title":"Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry","volume":"36","author":"Monti S","year":"2017","unstructured":"Monti S, Klersy C, Gorla R, et al.. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017, 36:753-61. 10.1007\/s10067-016-3528-y","journal-title":"Clin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02391-w","article-title":"Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients","volume":"22","author":"Bywall KS","year":"2020","unstructured":"Bywall KS, Kihlbom U, Hansson M, Falahee M, Raza K, Baecklund E, Veldwijk J. Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients. Arthritis Res Ther. 2020, 22:288. 10.1186\/s13075-020-02391-w","journal-title":"Arthritis Res Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1544892","article-title":"Upadacitinib for the treatment of rheumatoid arthritis","volume":"15","author":"Serhal L","year":"2019","unstructured":"Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019, 15:13-25. 10.1080\/1744666X.2019.1544892","journal-title":"Expert Rev Clin Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1782049","article-title":"A review of upadacitinib in rheumatoid arthritis","volume":"30","author":"Tanaka Y","year":"2020","unstructured":"Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020, 30:779-87. 10.1080\/14397595.2020.1782049","journal-title":"Mod Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01211-z","article-title":"Upadacitinib: first approval","volume":"79","author":"Duggan S","year":"2019","unstructured":"Duggan S, Keam SJ. Upadacitinib: first approval. Drugs. 2019, 79:1819-28. 10.1007\/s40265-019-01211-z","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka K","year":"2004","unstructured":"Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004, 5:253. 10.1186\/gb-2004-5-12-253","journal-title":"Genome Biol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.5.1603","article-title":"Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction","volume":"86","author":"Wilks AF","year":"1989","unstructured":"Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989, 86:1603-7. 10.1073\/pnas.86.5.1603","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee S","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017, 77:521-46. 10.1007\/s40265-017-0701-9","journal-title":"Drugs"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12164","article-title":"Therapeutic targeting of the Jak\/STAT pathway","volume":"114","author":"Aittom\u00e4ki S","year":"2014","unstructured":"Aittom\u00e4ki S, Pesu M. Therapeutic targeting of the Jak\/STAT pathway. Basic Clin Pharmacol Toxicol. 2014, 114:18-23. 10.1111\/bcpt.12164","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3109\/08977194.2012.660936","article-title":"Biology and significance of the JAK\/STAT signalling pathways","volume":"30","author":"Kiu H","year":"2012","unstructured":"Kiu H, Nicholson SE. Biology and significance of the JAK\/STAT signalling pathways. Growth Factors. 2012, 30:88-106. 10.3109\/08977194.2012.660936","journal-title":"Growth Factors"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00667","article-title":"Kinase inhibitors for the treatment of immunological disorders: recent advances","volume":"61","author":"Bryan MC","year":"2018","unstructured":"Bryan MC, Rajapaksa NS. Kinase inhibitors for the treatment of immunological disorders: recent advances. J Med Chem. 2018, 61:9030-58. 10.1021\/acs.jmedchem.8b00667","journal-title":"J Med Chem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112155","article-title":"Janus kinases (JAKs): the efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders","volume":"192","author":"Xu P","year":"2020","unstructured":"Xu P, Shen P, Yu B, et al.. Janus kinases (JAKs): the efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. Eur J Med Chem. 2020, 192:112155. 10.1016\/j.ejmech.2020.112155","journal-title":"Eur J Med Chem"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.03.041","article-title":"The regulation of JAKs in cytokine signaling and its breakdown in disease","volume":"118","author":"Hammar\u00e9n HM","year":"2019","unstructured":"Hammar\u00e9n HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019, 118:48-63. 10.1016\/j.cyto.2018.03.041","journal-title":"Cytokine"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82887","article-title":"Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis","volume":"126","author":"Yasuda T","year":"2016","unstructured":"Yasuda T, Fukada T, Nishida K, et al.. Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis. J Clin Invest. 2016, 126:2064-76. 10.1172\/JCI82887","journal-title":"J Clin Invest"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.12932\/AP0630.34.2.2016","article-title":"Association between JAK1 gene polymorphisms and susceptibility to allergic rhinitis","volume":"34","author":"Shen Y","year":"2016","unstructured":"Shen Y, Liu Y, Ke X, Kang HY, Hu GH, Hong SL. Association between JAK1 gene polymorphisms and susceptibility to allergic rhinitis. Asian Pac J Allergy Immunol. 2016, 34:124-9. 10.12932\/AP0630.34.2.2016","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5397.2258","article-title":"Interleukin-13: central mediator of allergic asthma","volume":"282","author":"Wills-Karp M","year":"1998","unstructured":"Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science. 1998, 282:2258-61. 10.1126\/science.282.5397.2258","journal-title":"Science"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa896","article-title":"JAK1 inhibition and inflammatory bowel disease","volume":"60","author":"Harris C","year":"2021","unstructured":"Harris C, Cummings JR. JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxford). 2021, 60:ii45-51. 10.1093\/rheumatology\/keaa896","journal-title":"Rheumatology (Oxford)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen AT","year":"2019","unstructured":"Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019, 33:15-32. 10.1007\/s40259-019-00333-w","journal-title":"BioDrugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.04.008","article-title":"Discovery of a class of highly potent Janus Kinase 1\/2 (JAK1\/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling","volume":"29","author":"Zak M","year":"2019","unstructured":"Zak M, Hanan EJ, Lupardus P, et al.. Discovery of a class of highly potent Janus Kinase 1\/2 (JAK1\/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. Bioorg Med Chem Lett. 2019, 29:1522-31. 10.1016\/j.bmcl.2019.04.008","journal-title":"Bioorg Med Chem Lett"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz DM","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017, 16:843-62. 10.1038\/nrd.2017.201","journal-title":"Nat Rev Drug Discov"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01397","article-title":"A dual Inhibition, a better solution: development of a JAK1\/TYK2 inhibitor","volume":"61","author":"Menet CJ","year":"2018","unstructured":"Menet CJ. A dual Inhibition, a better solution: development of a JAK1\/TYK2 inhibitor. J Med Chem. 2018, 61:8594-6. 10.1021\/acs.jmedchem.8b01397","journal-title":"J Med Chem"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski ST","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, et al.. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019, 62:8973-95. 10.1021\/acs.jmedchem.9b00444","journal-title":"J Med Chem"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.150","article-title":"Targeting JAK kinase in solid tumors: emerging opportunities and challenges","volume":"35","author":"Buchert M","year":"2016","unstructured":"Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016, 35:939-51. 10.1038\/onc.2015.150","journal-title":"Oncogene"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.229","article-title":"JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science","volume":"22","author":"Kilpivaara O","year":"2008","unstructured":"Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia. 2008, 22:1813-7. 10.1038\/leu.2008.229","journal-title":"Leukemia"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2174\/0929867311320090004","article-title":"JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms","volume":"20","author":"Treli\u0144ski J","year":"2013","unstructured":"Treli\u0144ski J, Robak T. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms. Curr Med Chem. 2013, 20:1147-61. 10.2174\/0929867311320090004","journal-title":"Curr Med Chem"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen C","year":"2011","unstructured":"Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011, 96:450-3. 10.3324\/haematol.2010.033191","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.43","article-title":"Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition","volume":"31","author":"Leroy E","year":"2017","unstructured":"Leroy E, Constantinescu SN. Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition. Leukemia. 2017, 31:1023-38. 10.1038\/leu.2017.43","journal-title":"Leukemia"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas J","year":"2012","unstructured":"Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012, 18:3008-14. 10.1158\/1078-0432.CCR-11-3145","journal-title":"Clin Cancer Res"},{"key":"ref43","article-title":"Jakafi (Ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera","volume":"8","author":"Raedler LA","year":"2015","unstructured":"Raedler LA. Jakafi (Ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera. Am Health Drug Benefits. 2015, 8:75-9.","journal-title":"Am Health Drug Benefits"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.43","article-title":"Pacritinib (SB1518), a JAK2\/FLT3 inhibitor for the treatment of acute myeloid leukemia","volume":"1","author":"Hart S","year":"2011","unstructured":"Hart S, Goh KC, Novotny-Diermayr V, et al.. Pacritinib (SB1518), a JAK2\/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011, 1:e44. 10.1038\/bcj.2011.43","journal-title":"Blood Cancer J"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01348","article-title":"Discovery of potent and orally effective dual Janus kinase 2\/FLT3 inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms","volume":"62","author":"Yang T","year":"2019","unstructured":"Yang T, Hu M, Qi W, et al.. Discovery of potent and orally effective dual Janus kinase 2\/FLT3 inhibitors for the treatment of acute myelogenous leukemia and myeloproliferative neoplasms. J Med Chem. 2019, 62:10305-20. 10.1021\/acs.jmedchem.9b01348","journal-title":"J Med Chem"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu X","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021, 6:402. 10.1038\/s41392-021-00791-1","journal-title":"Signal Transduct Target Ther"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25153321","article-title":"Inside perspective of the synthetic and computational toolbox of JAK inhibitors: recent updates","volume":"25","author":"Coricello A","year":"2020","unstructured":"Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside perspective of the synthetic and computational toolbox of JAK inhibitors: recent updates. Molecules. 2020, 25:3321. 10.3390\/molecules25153321","journal-title":"Molecules"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: first global approval","volume":"77","author":"Markham A","year":"2017","unstructured":"Markham A. Baricitinib: first global approval. Drugs. 2017, 77:697-704. 10.1007\/s40265-017-0723-3","journal-title":"Drugs"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair HA","year":"2019","unstructured":"Blair HA. Fedratinib: first approval. Drugs. 2019, 79:1719-25. 10.1007\/s40265-019-01205-x","journal-title":"Drugs"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01131-y","article-title":"Peficitinib: first global approval","volume":"79","author":"Markham A","year":"2019","unstructured":"Markham A, Keam SJ. Peficitinib: first global approval. Drugs. 2019, 79:887-91. 10.1007\/s40265-019-01131-y","journal-title":"Drugs"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: first approval","volume":"80","author":"Dhillon S","year":"2020","unstructured":"Dhillon S. Delgocitinib: first approval. Drugs. 2020, 80:609-15. 10.1007\/s40265-020-01291-2","journal-title":"Drugs"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01439-0","article-title":"Filgotinib: first approval","volume":"80","author":"Dhillon S","year":"2020","unstructured":"Dhillon S, Keam SJ. Filgotinib: first approval. Drugs. 2020, 80:1987-97. 10.1007\/s40265-020-01439-0","journal-title":"Drugs"},{"key":"ref53","unstructured":"Fact sheet for healthcare providers. emergency use authorization (EUA) of baricitinib. (2022). Accessed: September 9, 2023: https:\/\/www.fda.gov\/media\/143823\/download."},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.918604","article-title":"Selective JAK inhibitors in development for rheumatoid arthritis","volume":"23","author":"Norman P","year":"2014","unstructured":"Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014, 23:1067-77. 10.1517\/13543784.2014.918604","journal-title":"Expert Opin Investig Drugs"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK\u20101 inhibitor, after short\u2010term treatment of rheumatoid arthritis: results of two randomized phase IIa trials","volume":"69","author":"Vanhoutte F","year":"2017","unstructured":"Vanhoutte F, Mazur M, Voloshyn O, et al.. Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK\u20101 inhibitor, after short\u2010term treatment of rheumatoid arthritis: results of two randomized phase IIa trials. Arthritis Rheumatol. 2017, 69:1949-59. 10.1002\/art.40186","journal-title":"Arthritis Rheumatol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens R","year":"2017","unstructured":"Westhovens R, Taylor PC, Alten R, et al.. Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017, 76:998-1008. 10.1136\/annrheumdis-2016-210104","journal-title":"Ann Rheum Dis"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease P","year":"2018","unstructured":"Mease P, Coates LC, Helliwell PS, et al.. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018, 392:2367-77. 10.1016\/S0140-6736(18)32483-8","journal-title":"Lancet"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2016.12.001","article-title":"A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model","volume":"133","author":"Ito M","year":"2017","unstructured":"Ito M, Yamazaki S, Yamagami K, et al.. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017, 133:25-33. 10.1016\/j.jphs.2016.12.001","journal-title":"J Pharmacol Sci"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease\u2010modifying antirheumatic drugs in the treatment of moderate\u2010to\u2010severe rheumatoid arthritis","volume":"69","author":"Genovese MC","year":"2017","unstructured":"Genovese MC, Greenwald M, Codding C, et al.. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease\u2010modifying antirheumatic drugs in the treatment of moderate\u2010to\u2010severe rheumatoid arthritis. Arthritis Rheumatol. 2017, 69:932-42. 10.1002\/art.40054","journal-title":"Arthritis Rheumatol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1739649","article-title":"Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials","volume":"21","author":"Tanaka Y","year":"2020","unstructured":"Tanaka Y, Izutsu H. Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert Opin Pharmacother. 2020, 21:1015-25. 10.1080\/14656566.2020.1739649","journal-title":"Expert Opin Pharmacother"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02247-3","article-title":"Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan","volume":"22","author":"Takeuchi T","year":"2020","unstructured":"Takeuchi T, Tanaka Y, Tanaka S, et al.. Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Res Ther. 2020, 22:155. 10.1186\/s13075-020-02247-3","journal-title":"Arthritis Res Ther"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000559803.24361.5e","article-title":"Tofacitinib trial prompts FDA review of adverse effects","volume":"119","author":"Aschenbrenner DS","year":"2019","unstructured":"Aschenbrenner DS. Tofacitinib trial prompts FDA review of adverse effects. Am J Nurs. 2019, 119:25. 10.1097\/01.NAJ.0000559803.24361.5e","journal-title":"Am J Nurs"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1159\/000513938","article-title":"Topical tofacitinib: a Janus kinase inhibitor for the treatment of vitiligo in an adolescent patient","volume":"13","author":"Berbert Ferreira S","year":"2021","unstructured":"Berbert Ferreira S, Berbert Ferreira R, Neves Neto AC, Assef SM, Scheinberg M. Topical tofacitinib: a Janus kinase inhibitor for the treatment of vitiligo in an adolescent patient. Case Rep Dermatol. 2021, 13:190-4. 10.1159\/000513938","journal-title":"Case Rep Dermatol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera CC","year":"2022","unstructured":"Ayala-Aguilera CC, Valero T, Lorente-Mac\u00edas \u00c1, Baillache DJ, Croke S, Unciti-Broceta A. Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis. J Med Chem. 2022, 65:1047-131. 10.1021\/acs.jmedchem.1c00963","journal-title":"J Med Chem"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.820586","article-title":"The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single centre experience","volume":"10","author":"Kostik MM","year":"2022","unstructured":"Kostik MM, Raupov RK, Suspitsin EN, et al.. The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single centre experience. Front Pediatr. 2022, 10:820586. 10.3389\/fped.2022.820586","journal-title":"Front Pediatr"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2038134","article-title":"Tofacitinib for the treatment of active ankylosing spondylitis in adults","volume":"18","author":"Mohanakrishnan R","year":"2022","unstructured":"Mohanakrishnan R, Beier S, Deodhar A. Tofacitinib for the treatment of active ankylosing spondylitis in adults. Expert Rev Clin Immunol. 2022, 18:273-80. 10.1080\/1744666X.2022.2038134","journal-title":"Expert Rev Clin Immunol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann R","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, et al.. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012, 367:495-507. 10.1056\/NEJMoa1109071","journal-title":"N Engl J Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven RF","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, et al.. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012, 367:508-19. 10.1056\/NEJMoa1112072","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde D","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, et al.. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013, 65:559-70. 10.1002\/art.37816","journal-title":"Arthritis Rheum"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman D","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al.. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017, 377:1525-36. 10.1056\/NEJMoa1615977","journal-title":"N Engl J Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease P","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al.. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017, 377:1537-50. 10.1056\/NEJMoa1615975","journal-title":"N Engl J Med"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn WJ","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012, 367:616-24. 10.1056\/NEJMoa1112168","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","volume":"143","author":"Huang Z","year":"2019","unstructured":"Huang Z, Lee PY, Yao X, Zheng S, Li T. Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis. Pediatrics. 2019, 143:10.1542\/peds.2018-2845","journal-title":"Pediatrics"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13146","article-title":"Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - analyses of phase III clinical trials","volume":"15","author":"Muensterman E","year":"2022","unstructured":"Muensterman E, Engelhardt B, Gopalakrishnan S, Anderson JK, Mohamed MF. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - analyses of phase III clinical trials. Clin Transl Sci. 2022, 15:267-78. 10.1111\/cts.13146","journal-title":"Clin Transl Sci"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen JS","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al.. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019, 393:2303-11. 10.1016\/S0140-6736(19)30419-2","journal-title":"Lancet"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01930-4","article-title":"Economic benefit from improvements in quality of life with upadacitinib: comparisons with tofacitinib and methotrexate in patients with rheumatoid arthritis","volume":"38","author":"Bergman M","year":"2021","unstructured":"Bergman M, Tundia N, Yang M, Orvis E, Clewell J, Bensimon A. Economic benefit from improvements in quality of life with upadacitinib: comparisons with tofacitinib and methotrexate in patients with rheumatoid arthritis. Adv Ther. 2021, 38:5649-61. 10.1007\/s12325-021-01930-4","journal-title":"Adv Ther"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00379-9","article-title":"Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from SELECT-PsA 1","volume":"8","author":"Strand V","year":"2021","unstructured":"Strand V, Mease PJ, Soriano ER, et al.. Improvement in patient-reported outcomes in patients with psoriatic arthritis treated with upadacitinib versus placebo or adalimumab: results from SELECT-PsA 1. Rheumatol Ther. 2021, 8:1789-808. 10.1007\/s40744-021-00379-9","journal-title":"Rheumatol Ther"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes IB","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, et al.. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med. 2021, 384:1227-39. 10.1056\/NEJMoa2022516","journal-title":"N Engl J Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00410-z","article-title":"Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials","volume":"9","author":"Burmester GR","year":"2022","unstructured":"Burmester GR, Winthrop K, Blanco R, et al.. Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials. Rheumatol Ther. 2022, 9:521-39. 10.1007\/s40744-021-00410-z","journal-title":"Rheumatol Ther"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2039121","article-title":"Comparing available JAK inhibitors for treating patients with psoriasis","volume":"18","author":"Funk PJ","year":"2022","unstructured":"Funk PJ, Perche PO, Singh R, Kelly KA, Feldman SR. Comparing available JAK inhibitors for treating patients with psoriasis. Expert Rev Clin Immunol. 2022, 18:281-94. 10.1080\/1744666X.2022.2039121","journal-title":"Expert Rev Clin Immunol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese MC","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al.. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018, 391:2513-24. 10.1016\/S0140-6736(18)31116-4","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/195961-fda-approved-janus-kinase-signal-transducer-and-activator-of-transcription-jak-stat-inhibitors-for-managing-rheumatoid-arthritis-a-narrative-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:55:33Z","timestamp":1715270133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/195961-fda-approved-janus-kinase-signal-transducer-and-activator-of-transcription-jak-stat-inhibitors-for-managing-rheumatoid-arthritis-a-narrative-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":81,"URL":"https:\/\/doi.org\/10.7759\/cureus.59978","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}